NewsRoom Articles - Page 436 of 587

MondayApr 15, 2019 4:20 pm

420 with CNW – New York City Council Wants to End Employee Drug Testing

As New York State gets closer to legalizing recreational marijuana, the city council of New York has voted in favor of a bill that will ban employers from subjecting prospective employees to pre-employment cannabis tests. If enacted into law, this bill will be a trailblazer because no other city or municipality in the U.S. has passed such a law explicitly stating that employers are no longer allowed to test job applicants for marijuana before considering them for employment. The bill contains a clause that it will only be enacted a minimum of one year after the bill has been passed.…

MondayApr 15, 2019 1:06 pm

4 Benefits of Using Cannabis to Replace Your Depression Medication

Antidepressant medications have become more popular than ever. According to the American Psychology Association, the number of Americans treated with antidepressants has increased by 64% from 1999 to 2014. While there may be a number of factors contributing to the increased use of this category of drugs, its use does have some big downsides. The use of antidepressants is controversial because of their harsh side-effects, withdrawal difficulty, and even their overall effectiveness. People are now searching for alternatives to antidepressants, and are finding them in surprising places. One antidepressant alternative is gaining more popularity: cannabis. As cannabis becomes legal in more…

MondayApr 15, 2019 12:14 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing DehydraTECH Drug Delivery Platform, Innovative Products

Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology The company boasts a portfolio of unique products Lexaria continues to conduct research regarding DehydraTECH technology for oral nicotine Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Lexaria is the only global company with patents issued for the oral delivery of all cannabinoids. The company has developed and out-licenses its innovative and cost-effective DehydraTECH drug delivery platform. This technology changes the way that edible cannabinoids enter the body. DehydraTECH delivery technology offers a viable and…

MondayApr 15, 2019 11:46 am

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Marks Ninth Consecutive Quarter of Revenue Growth

Wildflower Brands Inc. sees annualized revenues exceeding $1 million for online sales The company’s diverse brands service customers nationwide, totaling distribution in over 300 stores The CBD product market is estimated to grow to $22 billion by 2022 and $75 billion by 2030 Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a Vancouver-based cannabis company focused on developing and designing branded products in the cannabis sector, intends to become a global wellness leader through its strategic varied brands in the industry. Wildflower Brands recently achieved more than 300 percent organic growth in online sales since January 2018, seeing annualized revenues exceeding…

MondayApr 15, 2019 10:25 am

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) Logs First Premium Cannabis Sales Grown in World-Class Cultivation Facility

2018 major milestones included launch of medicinal and recreational sales channels Company sold nearly 406 kilograms of premium cannabis, despite having only 20 percent of Kelowna 1 grow rooms operational during Q4 2018 Flowr optimizes yields, producing premium and ultra-premium cannabis products with a goal of no irradiation, to maximize profitability The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Canadian licensed producer of premium cannabis products, recently shared details of several milestones achieved during the fourth quarter of 2018 that included the company’s first recorded revenues, with nearly 260 kilograms of premium cannabis grown in-house during the period, despite only 20…

MondayApr 15, 2019 4:20 am

420 with CNW – Cannabis Inhalers Could Be the Next Asthma and Cancer Pain Medication

Whole smoking is the most common administration method for medical cannabis, not all patients are willing or able to use this method. For example, those who have respiratory challenges like asthma are unable to smoke cannabis because it may aggravate their condition. Terminally ill patients may also find it hard to smoke marijuana as part of their treatment. For such patients, two Israeli companies have teamed up to develop cannabis inhalers through which they can take their medication. The two firms are Panaxia Pharmaceuticals and Rafa Pharmaceuticals. The two companies are working together to bring marijuana inhalers to the market…

FridayApr 12, 2019 4:20 pm

420 with CNW – Cumbersome UK Medical Cannabis Program Forces Parents to Resort to Smuggling

Legally, patients who qualify can access medical cannabis across the UK ever since an enabling law paved the way for this treatment to be available from November 1, 2018. However, the reality is another thing altogether as patients are made to jump endless hoops in order to access medical marijuana through the National Health Service (NHS). The cumbersome bureaucratic system has compelled many desperate parents of kids who badly need medical marijuana to resort to smuggling the medicine from other countries. Emma Appleby is one of those parents, and her story is heart-wrenching. She says her daughter, aged nine, suffers…

FridayApr 12, 2019 11:37 am

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) Aiming to Provide Non-Irradiated Cannabis Products to Growing User Base

A majority of Canadian cannabis users identified quality and safety as top factors in choosing where to purchase cannabis Canada’s Shoppers Drug Mart is now the exclusive direct-to-patient online provider of FlowrRx products Flowr grows premium cannabis with a goal of non-irradiation using production methods that are expected to generate high crop yields at low operating costs Medicinal cannabis patients in Canada are rightly concerned about how cannabis products prescribed by their physicians are produced. According to Canada’s national statistical agency, Statistics Canada, 76 percent of medical cannabis patients responding to the Q4 2018 ‘National Cannabis Survey’ identified quality and…

FridayApr 12, 2019 10:22 am

VPR Brands, LP (VPRB) Riding Rising Tide of Vaping Product Popularity with Lifestyle Brands

Vaping is growing in popularity in the United States and internationally, driving cannabis concentrate sales toward a forecast reach of $47.11 billion by 2025 VPR Brands has built on the successful acquisition of Vapor Corp. technologies and has recently been growing into the cannabidiol (CBD) derivatives space VPR Brands’ GoldLine Hemp products are also finding a niche in the convenience store market as a variety of CBD-free hemp edibles Vaporizers and e-cigarettes have been enjoying growing popularity in recent years, becoming the largest driver behind cannabis concentrate sales and maintaining a position as the second-largest marijuana product category in the…

FridayApr 12, 2019 9:58 am

This Week in Cannabis: Florida Patients Rightfully Upset Over Latest Medical Cannabis Measure

It was another big week for cannabis news. Some progress, lots of drama, and major developments to keep your eye on... Is a cap on THC coming to Florida's medical cannabis program? What happened: A committee in Florida's House of Representatives passed a measure that would cap cannabis flower's potency at 10%. The bill now moves to the House floor where it's unclear at this time what the chances are of it passing. Why it matters: The battle to allow sales of cannabis flower went on for a long time in Florida, with Florida's Governor lifting the ban on cannabis…

News and publishing service for cannabis related companies

Contact us: 512.354.7000